{
    "nctId": "NCT05103826",
    "briefTitle": "A Study of SHR6390 Combined With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer",
    "officialTitle": "A Phase I Study to Evaluate Safety \u3001Tolerability \u3001 Pharmacokinetics and Efficacy of SHR6390 in Combination With Famitinib in the Treatment of ER + / HER2- Advanced Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "ER+ / HER2- Advanced Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 3,
    "primaryOutcomeMeasure": "(Safety Lead-in) dose limited toxicity (DLT) of SHR6390+famitinib in the first cycle",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Female subjects aged 18 to 75 years old\uff1b\n2. ECOG performance status 0-1;\n3. Life expectancy is not less than 12 weeks;\n4. Histological or cytological confirmation of ER+/HER2- recurrent/metastatic breast cancer;\n5. Participants with measurable disease must have at least one \"target lesion\" to be used to assess response on this protocol as defined by RECIST1.1;\n6. Adequate function of major organs;\n7. Voluntary participation in the study, signed informed consent, good compliance and willingness to cooperate with follow-up.\n\nExclusion Criteria:\n\n1. Confirmed diagnosis of HER2 positive disease;\n2. Participants who previously received SHR6390 or VEGFR inhibitors;\n3. Allergy to study drug or its components;\n4. Participated in other drug clinical trials within 4 weeks before the first dose;\n5. Other malignancies within 3 years, except cured non-melanoma skin cancer , skin basal cell carcinoma and squamous-cell carcinoma or carcinoma in situ of the cervix;\n6. Clinically significant cardiovascular and cerebrovascular diseases,including but not limited to severe acute myocardial infarction within 6 months before enrollment, unstable or severe angina, Congestive heart failure (New York heart association (NYHA) class \\> 2), or ventricular arrhythmia which need medical intervention\uff1b\n7. Tumor has invaded important blood vessels or the tumor is likely to invade important blood vessels and cause fatal hemorrhage during treatment;\n8. Urine routine test indicates urine protein \u2265(++), or 24-hour urine protein \\>1.0g;\n9. Active HBV/HCV/HIV infection;\n10. The investigators determined that other conditions were inappropriate for participation in this clinical trial\uff1b\n11. Pregnant or breast-feeding women;\n12. Central nervous system (CNS) invasion.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}